Jinseok Kim

Dr. Jinseok Kim


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2014 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
HKHyun Woo Kim
Hyun Woo Kim
CLChang-Keun Lee
Chang-Keun Lee
HCHoon-Suk Cha
Hoon-Suk Cha
JCJung-Yoon Choe
Jung-Yoon Choe
EPEun-Jung Park
Eun-Jung Park
JKJinseok Kim
Jinseok Kim

23 November 2020 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
CCChangmin Choi
Changmin Choi
WJWooseong Jeong
Wooseong Jeong
BGByeongzu Ghang
Byeongzu Ghang
YPYonggeun Park
Yonggeun Park
CHChanglim Hyun
Changlim Hyun
JKJinseok Kim
Jinseok Kim
Background: Interleukin-6 (IL-6) is involved in fibroblast-like synoviocyte (FLS) activation and promotes pannus formation and bone and cartilage destruction in rheumatoid arthritis (RA). Cysteine-rich 61 (Cyr61) protein regulates cell proliferation, migration, and differentiation. The aim of this study was to investigate the role of Cyr61 in RA-FLS migration and invasion after IL-6 stimulation. Methods: Western blotting, immunohistochemistry, reverse transcription-polymerase chain reaction, and real time-polymerase chain reaction were used to examine protein and mRNA levels of Cyr61, matrix metalloproteinases (MMPs), and other signalling proteins. Knockdown of gene expression was performed with siRNA, and RNA sequencing was performed for differential gene analysis. Migration and invasion were assessed by wound healing and Boyden chamber assays. Results: Cyr61 levels were elevated in FLSs from RA patients compared to those in osteoarthritis patients. Control and IL-6-treated FLSs showed differential gene expression. IL-6 stimulated protein synthesis of Cyr61, which was attenuated by the extracellular signal-related kinase 1/2 (ERK 1/2) inhibitor, PD98059, and knockdown of early growth response 3 (EGR3), but not of JUN. IL-6-induced Cyr61 protein synthesis increased expression of MMP2. Cyr61 promoted FLS migration and invasion in an autocrine manner. Knockdown of CYR61 and a neutralising antibody attenuated Cyr61 synthesis and IL-6-induced FLS migration. Conclusions: By modulating the ERK/EGR3 pathway, IL-6 stimulated Cyr61 production and in turn increased invasiveness of FLS. Our data suggest that Cyr61 might be a potential target to prevent the progression of joint damage in RA.

14 May 2020 in Lupus
Verified
Journal Article
Closed access
PDF file
HKHyunwoo Kim
Hyunwoo Kim
TKTaehee Kim
Taehee Kim
MKMiyeon Kim
Miyeon Kim
HLHwa Young Lee
Hwa Young Lee
YKYunmi Kim
Yunmi Kim
JKJinseok Kim
Jinseok Kim
Objectives: The aims of this study were to clarify the activation of complement pathways in patients with lupus nephritis (LN), and to elucidate the association between these complement activation types and clinical outcomes. Methods: We enrolled 115 patients with biopsy-proven LN from 2003 to 2016 from the lupus cohort at the Busan Paik Hospital and the Jeju National University Hospital in Korea. The patients were divided into two groups based on the patterns of glomerular complements deposits. The presence of C1q, C4 and/or C3 deposits in the glomerulus was considered evidence for the activation of the classical pathway with or without alternative pathway activation (group 1, N = 93), and glomerular C3 deposition without C1q and C4 deposits was considered as a marker for the alternative pathway limited activation (group 2, N = 22). The study end point was progression of kidney disease defined as a ≥50% reduction in estimated glomerular filtration rate from baseline values or advancement to end-stage renal disease. Results: The mean estimated glomerular filtration rate and median urine protein-to-creatinine ratio of the patients were 85.7 ± 32.4 mL/min/1.73 m2 and 3.1 g/g, respectively, at the time of kidney biopsy. Forty-nine patients (43%) had nephrotic range of proteinuria. Compared to group 1 patients, those in group 2 were older, were more likely to be males and were more hypertensive. In addition, plasma C3 and C4 levels were significantly lower in group 1 patients compared to those in group 2. Moreover, anti-dsDNA concentration was significantly higher in group 1 patients compared to those in group 2. The mean follow-up time was 5.4 ± 3.4 years. The rates of response to one-year immunosuppressive treatment were poorer in group 2 patients compared to those in group 1. During the follow-up time, the progression of kidney disease was significantly higher in group 2 than in group 1 patients. Conclusion: This study showed that there was alternative complement pathway limited activation in the renal tissue in a small number of patients with LN, and these patients had worse renal outcomes compared to patients with glomerular classical complement pathway activation with or without alternative pathway activation.

15 November 2024 in Kidney International
Verified
Journal Article
Closed access
BGByeongzu Ghang
Byeongzu Ghang
JPJino Park
Jino Park
JLJi Sung Lee
Ji Sung Lee
JLJoon Seo Lim
Joon Seo Lim
HKHyunwoo Kim
Hyunwoo Kim
BYBin Yoo
Bin Yoo

9 August 2012 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
GSGil Myeong Seong
Gil Myeong Seong
JKJo-Heon Kim
Jo-Heon Kim
GLGil Chai Lim
Gil Chai Lim
JKJinseok Kim
Jinseok Kim

22 June 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
BGByeongzu Ghang
Byeongzu Ghang
JLJi Sung Lee
Ji Sung Lee
JCJihye Choi
Jihye Choi
JKJinseok Kim
Jinseok Kim
BYBin Yoo
Bin Yoo
Objectives The Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial suggested a higher risk of cardiovascular (CV) death from febuxostat than from allopurinol. However, a significant number of patients died after discontinuation of febuxostat or allopurinol. We investigated whether major adverse cardiovascular events (MACE) and CV death were increased because of discontinuation of febuxostat or allopurinol using the CARES trial data. Methods We compared the MACE that occurred during administration and after discontinuation in the initial phase after discontinuation, and we compared the CV and non-CV mortality rates in the initial phase after discontinuation to determine the impact of discontinuation of febuxostat or allopurinol. Results Among 6190 patients, the incidence rate per 100 person-years for MACE was 3.11 during administration and 6.71 after discontinuation. MACE was significantly increased after discontinuation compared with that during administration within 1 month (HR 7.40; 95% CI 5.38 to 10.17) and 6 months (HR 5.22; 95% CI 4.26 to 6.39). In the analysis excluding death induced by adverse events that occurred up to 1 day after the last medication, the CV mortality rate was higher than the non-CV mortality rate within 6 months (45.7% vs 27.9%, p=0.0001). In addition, changes in serum uric acid levels from baseline to the last measurement before discontinuation were significantly associated with higher MACE risk after drug discontinuation (HR 1.14; 95% CI 1.04 to 1.26). Conclusions MACE and CV death were increased in the initial stage after discontinuation of febuxostat or allopurinol in patients with gout.